[AKBA] Akebia Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 325.49 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 10.6 Change: 0.51 (5.05%)
Ext. hours: Change: 0 (0%)

chart AKBA

Refresh chart

Description: Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is AKB-6548, a HIF-PH inhibitor, which is in Phase IIb clinical trials for patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. The company is also developing a development program for patients dependent on dialysis. Akebia Therapeutics, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding37.98 M EPS-4.05 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-3.48
P/E To EPS Growth P/S P/BV3.44 Price/Cash Per Share3.24
Price/Free Cash Flow ROA-36.76% ROE-40.2% ROI
Current Ratio11.62 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities50 K Cash From Investing Activities3.4 M Cash From Operating Activities-8.35 M Gross Profit
Net Profit-10.7 M Operating Profit-10.79 M Total Assets103.46 M Total Current Assets102.69 M
Total Current Liabilities8.84 M Total Debt Total Liabilities8.85 M Total Revenue
Technical Data
High 52 week18.15 Low 52 week5.39 Last close6.18 Last change0.65%
RSI54.95 Average true range0.43 Beta1.18 Volume394.84 K
Simple moving average 20 days3.15% Simple moving average 50 days-14.05% Simple moving average 200 days-36.77%
Performance Data
Performance Week-4.92% Performance Month-19% Performance Quart-28.22% Performance Half-35.02%
Performance Year-65.08% Performance Year-to-date11.75% Volatility daily4.97% Volatility weekly11.12%
Volatility monthly22.79% Volatility yearly78.95% Relative Volume2357.44% Average Volume1.01 M
New High New Low

News

2019-12-03 16:06:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-12-02 08:57:01 | Options Traders Expect Huge Moves in Akebia Therapeutics AKBA Stock

2019-12-02 05:09:47 | Introducing Akebia Therapeutics NASDAQ:AKBA, The Stock That Slid 52% In The Last Five Years

2019-11-27 09:45:31 | 5 “Strong Buy” Biotech Stocks With More Than 80% Upside

2019-11-26 12:26:44 | Large Option Trader Betting On Biotech Stock Akebia Following Insider Buys

2019-11-21 08:00:00 | Akebia Therapeutics to Present at Upcoming Investor Conferences

2019-11-18 21:32:05 | Edited Transcript of AKBA earnings conference call or presentation 12-Nov-19 2:00pm GMT

2019-11-12 09:15:02 | Akebia Therapeutics AKBA Reports Q3 Loss, Misses Revenue Estimates

2019-11-12 07:57:00 | Akebia Secures $100 Million Non-Dilutive Term Loan Financing; Reports Third Quarter 2019 Financial Results

2019-11-12 07:20:31 | The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

2019-11-09 12:15:00 | Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease

2019-11-05 10:33:03 | Will Akebia Therapeutics AKBA Report Negative Earnings Next Week? What You Should Know

2019-11-04 16:05:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-11-01 09:18:53 | Can Akebia Therapeutics NASDAQ:AKBA Afford To Invest In Growth?

2019-10-30 09:30:19 | Akebia Therapeutics Inc AKBA Is Burning These Hedge Funds

2019-10-28 08:00:00 | Akebia Therapeutics to Report Third Quarter 2019 Financial Results and Discuss Recent Business Highlights

2019-10-24 08:00:00 | Akebia Announces Nine Abstracts Accepted for Presentation at the American Society of Nephrology Kidney Week 2019 Annual Meeting

2019-10-16 07:06:15 | The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch

2019-10-15 16:46:00 | Akebia Files Lawsuit Against CMS for 2018 Action Rescinding Medicare Part D Coverage of FDA-Approved Auryxia® for its Iron Deficiency Anemia Indication and Imposing a Prior Authorization Requirement for its Hyperphosphatemia Indication

2019-10-02 12:27:42 | Should You Worry About Akebia Therapeutics, Inc.'s NASDAQ:AKBA CEO Pay Cheque?

2019-09-24 08:00:00 | Akebia Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

2019-09-04 17:15:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-09-03 14:21:23 | In expense-laden biotech industry, here are the Mass. startups most in need of cash

2019-09-02 15:41:09 | How Does Akebia Therapeutics, Inc. NASDAQ:AKBA Affect Your Portfolio Volatility?

2019-08-11 02:57:29 | Edited Transcript of AKBA earnings conference call or presentation 8-Aug-19 1:00pm GMT

2019-08-09 23:51:34 | Akebia Therapeutics, Inc. AKBA Q2 2019 Earnings Call Transcript

2019-08-09 08:00:00 | Akebia Therapeutics to Participate in Upcoming Investor Conferences

2019-08-08 09:25:01 | Akebia Therapeutics AKBA Reports Q2 Loss, Tops Revenue Estimates

2019-08-08 08:00:00 | Akebia Therapeutics Reports Second Quarter 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights

2019-08-05 08:00:00 | Akebia Therapeutics® Announces Settlement of Auryxia® Patent Litigation with Par Pharmaceutical

2019-08-02 16:05:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-08-01 10:33:02 | Akebia Therapeutics AKBA May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2019-07-26 08:27:01 | What Type Of Shareholder Owns Akebia Therapeutics, Inc.'s NASDAQ:AKBA?

2019-07-25 08:00:00 | Akebia Therapeutics to Report Second Quarter 2019 Financial Results

2019-07-23 04:00:00 | Akebia Therapeutics Announces Submission of Vadadustat New Drug Application in Japan for Anemia Due to Chronic Kidney Disease by Collaboration Partner, MTPC

2019-07-11 08:00:00 | Akebia Therapeutics CEO, John P. Butler, Elected Chair of Kidney Care Partners

2019-07-10 08:00:00 | Akebia Therapeutics Announces Collaboration Partner’s Positive Top-line Results of Phase 3 Clinical Study of Riona® ferric citrate hydrate in Adult Patients with Iron Deficiency Anemia in Japan

2019-07-02 16:05:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-06-20 09:21:09 | When Can We Expect A Profit From Akebia Therapeutics, Inc. NASDAQ:AKBA?

2019-06-19 21:32:43 | Hedge Funds Are Dumping Akebia Therapeutics Inc AKBA

2019-06-11 07:30:00 | Akebia Therapeutics Launches AkebiaCares, an Enhanced Patient Access Program for People with Chronic Kidney Disease

2019-06-04 16:05:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-05-29 08:00:00 | Akebia Therapeutics to Participate in Upcoming Investor Conferences

2019-05-09 18:02:54 | Edited Transcript of AKBA earnings conference call or presentation 9-May-19 1:00pm GMT

2019-05-09 14:44:25 | Akebia Therapeutics, Inc. AKBA Q1 2019 Earnings Call Transcript

2019-05-09 13:16:36 | Here’s What Hedge Funds Think About Akebia Therapeutics Inc AKBA

2019-05-09 08:10:29 | Akebia Therapeutics: 1Q Earnings Snapshot

2019-05-09 08:00:00 | Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments

2019-05-08 11:45:07 | Seth Klarman Keeps Buying This Biotech Stock

2019-05-02 16:05:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4